Insights

Washington – January 2, 2020: Crowell & Moring elected eight lawyers to the firm’s partnership, effective January 1, 2020. The firm also promoted seven attorneys to the position of senior counsel, and 26 associates to the position of counsel. The new partners have been promoted from within the ranks of the firm’s Washington, Los Angeles, and San Francisco offices. The new partners have been promoted from across offices and practice groups, including White Collar & Regulatory Enforcement, Health Care, International Trade, Intellectual Property, Privacy & Cybersecurity, Government Contracts, Litigation, and Antitrust.

EDIT The U.S. Food and Drug Administration (FDA) walked back its policy that allowed COVID-19 antibody test kits to enter the market without agency review. In its original March 16 Final Guidance, FDA allowed commercial manufacturers to market and sell antibody test kits after internally validating their own products and notifying FDA. The Agency did not require emergency use authorization (EUA) as it did with PCR (molecular) testing, though seeking an EUA was “encouraged.”

In this issue:

In this issue:

During these difficult times global businesses must streamline and protect their supply chain operations, manage new sourcing, navigate border issues, keep abreast of rapidly changing regulations, and deal with contract disputes. Importers and other businesses in the supply chain who take key steps now may mitigate potential losses while ensuring compliant and efficient supply chains. Topics to be discussed include:

Join the Crowell & Moring trade team for a 30-minute update on the U.S.-China trade negotiations, the imposition of tariffs, and the continued escalation of tensions from the White House. Hear the latest on President Trump’s potential next steps, the status of the product exclusion process for Lists 1, 2, and 3, and how to respond to the recent announcement of List 4, covering virtually all the remaining U.S. imports from China.